Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.87 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6642082 | 0.81 | HTR1A (1.00) | HTR1ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7696681 | 0.79 | HTR1A (0.93) | HTR1ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6637002 | 0.78 | HTR1A (0.77) | HTR1ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6635628 | 0.77 | HTR1A (1.00) | HTR1ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6638832 | 0.77 | HTR1A (0.73) | HTR1ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7497631 | 0.76 | HTR1A (0.57) | HTR1ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6641848 | 0.76 | HTR1A (0.71) | HTR1ASLC6A4 | |
| SCHEMBL6637045 | 0.76 | HTR1A (0.70) | HTR1ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6639816 | 0.75 | HTR1A (0.81) | HTR1ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6635714 | 0.75 | HTR1A (0.69) | HTR1ASLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146871-A4 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2002-04-17 | — | — | EP | claimed |
| CN-1342074-A | Antidepressant heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2002-03-27 | — | — | CN | claimed |
| EP-1146871-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2001-10-24 | — | — | EP | claimed |
| US-6225324-B1 | POTENT INHIBITION OF 5-HT REUPTAKE; 1,3-DISUBSTITUTED PYRROLIDINE, 1,4-DISUBSTITUTED PIPERIDINE, OR 1,4-DISUBSTITUTED HEXAHYDROAZEPINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2001-05-01 | — | — | US | claimed |
| WO-2000044376-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| EP-1146871-A4 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2002-04-17 | — | — | EP | disclosed |
| CN-1342074-A | Antidepressant heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1146871-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6225324-B1 | POTENT INHIBITION OF 5-HT REUPTAKE; 1,3-DISUBSTITUTED PYRROLIDINE, 1,4-DISUBSTITUTED PIPERIDINE, OR 1,4-DISUBSTITUTED HEXAHYDROAZEPINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2001-05-01 | — | — | US | disclosed |
| WO-2000044376-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |